Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from solid tumours, metastases of ALL seldom involve the parenchyma but are isolated to the leptomeninges, which is an infrequent site for carcinomatous invasion. Although metastasis to the CNS occurs across all subtypes of Acute lymphoblastic leukemia, a unifying mechanism for invasion has not yet been determined. The basement membrane of these bridging vessels is enriched in laminin. The laminin receptor α6 integrin is expressed in most cases of ALL. Mice with Acute lymphoblastic leukemia xenografts were treated with either a PI3Kδ inhibitor, which decreased α6 integrin expression on ALL cells. Our data suggest that α6 integrin expression, which is common in ALL, allows cells to use neural migratory pathways to invade the CNS.
- Global Top Players in Intraocular Lens (IOL) Market
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- World Population Day 2018
- How are Nanobots Proving Their Excellence in the Healthcare Industry?
- Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
- Which Countries Top the Chart in Global Pharmaceutical Market?
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...Find More
Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL)
DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflic...Find More
Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults
Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has an...Find More
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.